<DOC>
	<DOCNO>NCT00081484</DOCNO>
	<brief_summary>This study ass efficacy safety intravenous ( iv ) subcutaneous ( sc ) Mircera , administer pre-filled syrinx , maintenance treatment renal anemia chronic kidney disease patient dialysis previously receive iv sc epoetin . The anticipated time study treatment 3-12 month target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Intravenous Subcutaneous Mircera Treatment Anemia Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic renal anemia ; dialysis therapy least 12 week screen ; receive iv sc epoetin least 8 week screen . woman pregnant , breastfeed use unreliable birth control method ; administration another investigational drug within 4 week screening , study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>